Prenetics names Brian Rosin as CFO effective December 31

Prenetics Global Limited (NASDAQ: PRE) has announced the appointment of Brian J. Rosin as its new Chief Financial Officer (CFO), effective December 31, 2026. The decision was communicated in a press release statement and is expected to be formalized during the Board of Directors' meeting on November 12, 2026. Rosin, who has been serving as CFO of IM8 since May 2026, will take on the role of CFO-designate until the end of the year, working alongside the outgoing CFO, Stephen Lo.

With IM8 representing the majority of Prenetics' revenue, the company will operate under a single CFO in the future. Rosin will lead the company's global finance organization and report directly to CEO Danny Yeung. Since joining Prenetics, Rosin has played a key role in the company's financial presentations and secured a $1 billion growth commitment financing from General Catalyst's Customer Value Fund.

Currently based in the United States, Rosin will help strengthen Prenetics' position in the largest market and primary capital market. Cindy Tat, who joined Prenetics in August 2026 as Vice President, Financial Controller, will also contribute to the finance leadership development in the United States. Tat brings over 16 years of experience in SEC reporting and SOX compliance from her previous roles at WM Technology and Iteris.

Stephen Lo will continue to serve as CFO until the end of December 2026, working with Rosin to ensure a smooth transition. Lo will then remain with the company as a Senior Advisor. Rosin's extensive background in finance leadership within premium consumer health and e-commerce makes him an ideal candidate for the role. He previously served as CFO and Senior Vice President of e-Commerce Operations at Wellbeam Consumer Health.

Prenetics is scheduled to report its third quarter 2026 financial results on November 18, 2026, and will host a live-streamed earnings event on Stocktwits at 8:30 a.m. Eastern Time.